Quarterly ResultApr 30, 2026, 06:12 AM
ANIK Q1 Revenue +13.2% to $29.6M; Net Loss $(5.1)M
AI Summary
Anika Therapeutics, Inc. reported a 13.2% increase in Q1 2026 revenue to $29.6 million, with gross profit rising 29.4% to $19.0 million. Despite revenue growth, the company's net loss widened slightly to $(5.1) million, and basic and diluted loss per share from continuing operations increased to $(0.37). The company also initiated a restructuring plan, recognizing $1.6 million in severance costs, and saw a significant decrease in cash and cash equivalents, partly due to increased stock repurchases.
Key Highlights
- ANIK Q1 2026 revenue increased 13.2% to $29.6 million from $26.2 million in Q1 2025.
- Gross profit rose 29.4% to $19.0 million in Q1 2026, up from $14.7 million in Q1 2025.
- Net loss for Q1 2026 was $(5.1) million, compared to $(4.9) million in Q1 2025.
- Basic and diluted loss per share from continuing operations was $(0.37) in Q1 2026, versus $(0.28) in Q1 2025.
- Cash and cash equivalents decreased to $41.0 million as of March 31, 2026, from $57.5 million at December 31, 2025.
- The company repurchased $8.7 million of common stock in Q1 2026, up from $4.0 million in Q1 2025.
- Recognized $1.6 million in severance and employee-related costs due to a workforce reduction in Q1 2026.
- Selling, general and administrative expenses increased to $17.8 million in Q1 2026 from $12.9 million in Q1 2025.
Price Impact
More from ANIK